Dipika Mohan

Graduate Student
MSTP Fellow

Biography

Dipika graduated from Washington University in St. Louis (Wash U) in 2014 with a Bachelor of Science in Mechanical Engineering, cum laude. During her undergraduate, she researched altered post-transcriptional regulation of gene expression in the pathogenesis of leukemia and pre-leukemic syndromes in the lab of Timothy Graubert, MD, at Wash U School of Medicine.

Dipika matriculated to the University of Michigan Medical School in 2014 to pursue MD and PhD degrees as a Medical Scientist Training Program (MSTP) Fellow. She completed two years of medical school and is currently in the PhD phase of her joint degree program. During her PhD, she is researching the rerouted biological pathways that distinguish aggressive adrenocortical carcinoma (ACC) in the lab of Gary Hammer, MD, PhD.

 

Diversity Ambassador

First Generation U.S. Citizen

 

Research Interests

Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland, and surgery remains the only therapy with potential to cure. Up to 75% of patients develop deadly metastatic disease, highlighting an urgent need for improved systemic agents. In The Cancer Genome Atlas study on ACC, we identified a rapidly recurrent and routinely fatal molecular subtype of ACC characterized by tumor CpG island hypermethylation and a unique transcriptional program and somatic alteration profile. My work is focused on 1.) developing molecular tools to enable accurate prospective identification of patients with this ACC subtype, and 2.) refining the understanding of molecular programs derailed in these tumors. Ultimately, we hope our studies will identify novel, personalized targeted therapeutic strategies efficacious at fighting this devastating disease.
 

Techniques

All molecular biology all the time. Email me!
 

Awards

Rogel Cancer Center MD/PhD Scholarship (2019-2020)
Endocrine Society Outstanding Abstract Award, ENDO 2019

Publications

Mohan DR*, Lerario AM*, Else T, Mukherjee B, Almeida MQ, Vinco M, Rege J, Mariani BMP, Zerbini MCN, Mendonca BB, Latronico AC, Marie SKN, Rainey WE, Giordano TJ, Fragoso MCBV^, Hammer GD^. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clinical Cancer Research. 2019 Jun 1;25(11):3276-3288. *,^equal contribution

Lerario AM, Mohan DR, Lirov R, Else T, Hammer GD, 2019, “83. Adrenal Tumors,” in DeVita VT, Lawrence TS, Rosenburg SA (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.

Mohan DR, Lerario AM, Hammer GD. Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era. Journal of the Endocrine Society. 2018 Sep 26;2(11):1259-1274.

Okeyo-Owuor T, White BS, Chatrikhi R,Mohan DR, Kim S, Griffith M, Ding L, Ketkar-Kulkarni S, Hundal J, Laird KM, Kielkopf CL, Ley TJ, Walter MJ, Graubert TA. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia. 2015 Apr;29(4):909-17.

Cancer Bio Mentor